{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000340.3:c.160G>A",
          "cDNA Change": {
            "transcript": "NM_000340.3",
            "ref": "G",
            "alt": "A",
            "position": "160"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T mutation in alpha-synuclein (SNCA) gene"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Familial Parkinson's Disease",
    "MONDO": "MONDO:0005311"
  },
  "Experiment Method": [
    {
      "Assay Method": "Immunohistochemical Analysis",
      "Material used": {
        "Material Source": "Human brain tissue",
        "Material Name": "Patients with A53T mutation",
        "Description": "Immunohistochemical analysis of brain tissues from patients with A53T mutation"
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.160G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Gain-of-function (promotes alpha-synuclein aggregation)",
          "Result Description": "Increased alpha-synuclein fibrillization and tau pathology observed in A53T patient tissues"
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Standard neurodegenerative disease criteria (absence of alpha-synuclein aggregation)",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Presence of alpha-synuclein fibrils and tau pathology confirmed via immunohistochemistry",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Biochemical Analysis",
      "Material used": {
        "Material Source": "Human brain tissue",
        "Material Name": "Patients with A53T mutation",
        "Description": "Biochemical analysis of alpha-synuclein and tau protein aggregation in A53T patient tissues"
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.160G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Gain-of-function (enhances protein aggregation)",
          "Result Description": "Significant increase in alpha-synuclein and tau protein aggregation levels in A53T patient tissues"
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Standard biochemical criteria (normal protein aggregation levels)",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Abnormal protein aggregation levels confirmed via biochemical assays",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Ultrastructural Characterization (Electron Microscopy)",
      "Material used": {
        "Material Source": "Human brain tissue",
        "Material Name": "Patients with A53T mutation",
        "Description": "Ultrastructural analysis of alpha-synuclein and tau pathology in A53T patient tissues"
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.160G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Gain-of-function (promotes aggregation into pathological structures)",
          "Result Description": "Ultrastructural evidence of alpha-synuclein and tau aggregates in A53T patient tissues"
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Standard ultrastructural criteria (absence of pathological aggregates)",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Presence of alpha-synuclein and tau pathological aggregates confirmed via ultrastructural analysis",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "In Vitro Fibrillization Studies",
      "Material used": {
        "Material Source": "Recombinant proteins",
        "Material Name": "Wild-type and A53T alpha-synuclein",
        "Description": "In vitro studies of alpha-synuclein and tau fibrillization using wild-type and A53T mutant proteins"
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.160G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Gain-of-function (accelerates fibrillization)",
          "Result Description": "A53T mutant alpha-synuclein exhibited significantly faster fibrillization kinetics compared to wild-type"
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly described in the literature"
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Standard in vitro fibrillization criteria (normal kinetics)",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Abnormal fibrillization kinetics confirmed via in vitro studies",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}